FindTrial
Sign In

Effect of myofascial release in tumor necrosis factor in individuals with low back pain.

Impact Of 3-Dimensional Myofascial Release on Tumor Necrosis Factor (TNF) Alpha Biomarker In Nonspecific Low Back Pain: A Randomized Controlled Trial - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065093
Enrollment
40
Registered
2024-04-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M958- Other specified acquired deformities of musculoskeletal system

Interventions

Intervention1: Experimental Group : Pre treatment samples will be collected and sent to laboratory for analysis. And then three dimensional myofascial release treatment is given for 8 sessions, and po

Sponsors

KLE Academy of Higher Education & Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Presenting with sub-acute and chronic low back pain =1 months. Within 30-50 years of age. Willing to participate in the study. Who can comprehend and are co-operative

Exclusion criteria

Exclusion criteria: Secondary pain or low back pain associated with a range of serious conditions The presence of a severe psychiatric disorder Substance dependence, neuro-inflammatory or neurodegenerative disorders , and immune-inflammatory disorders Current use of prescribed pain medication, except non-steroidal anti-inflammatory drugs and over-the-counter analgesics Pregnancy.

Design outcomes

Primary

MeasureTime frame
Inflammatory Biomarker TNF-a Timepoint: 4 weeks—

Secondary

MeasureTime frame
Modified Oswestry Low Back Pain Disability Questionnaire, Visual Analogue ScaleTimepoint: 4 weeks—

Countries

India

Contacts

Public ContactVijay Kage

KAHER Institute Of Physiotherapy

vijaykage@yahoo.in9845271899

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026